# Heikki Joensuu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/heikki-joensuu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 75,465 |
| Field | Gastrointestinal Tumor Research and Treatment |
| h-index | 128 |
| i10-index | 520 |
| Last Known Institution | Orion Corporation (Finland) |
| OpenAlex ID | https://openalex.org/A5090618504 |
| ORCID iD | https://orcid.org/0000-0003-0281-2507 |
| Works | 1,136 |

## Researcher papers

- [FinnGen provides genetic insights from a well-phenotyped isolated population](https://scholariq.org/papers/finngen-provides-genetic-insights-from-a-well-phenotyped-isolated-population/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice-guidelines-for/)
- [Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/bone-sarcomas-esmo-paedcan-euracan-clinical-practice-guidelines-for-diagnosis/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice/)
- [FinnGen: Unique genetic insights from combining isolated population and national health register data](https://scholariq.org/papers/finngen-unique-genetic-insights-from-combining-isolated-population-and-national/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice/)
- [Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice/)

## Researcher topics

- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Orion Corporation (Finland)](https://scholariq.org/institutions/orion-corporation-finland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.